WO2005065672A1 - Composition antivieillissement - Google Patents

Composition antivieillissement Download PDF

Info

Publication number
WO2005065672A1
WO2005065672A1 PCT/JP2005/000430 JP2005000430W WO2005065672A1 WO 2005065672 A1 WO2005065672 A1 WO 2005065672A1 JP 2005000430 W JP2005000430 W JP 2005000430W WO 2005065672 A1 WO2005065672 A1 WO 2005065672A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
aging
reduced coenzyme
crude drug
coenzyme
Prior art date
Application number
PCT/JP2005/000430
Other languages
English (en)
Inventor
Kenji Fujii
Taizo Kawabe
Hiroshi Kubo
Keiichi Higuchi
Original Assignee
Kaneka Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corporation filed Critical Kaneka Corporation
Priority to AU2005204044A priority Critical patent/AU2005204044B2/en
Priority to JP2006520582A priority patent/JP2007517761A/ja
Priority to CA002550186A priority patent/CA2550186A1/fr
Priority to EP05703669A priority patent/EP1701716A1/fr
Publication of WO2005065672A1 publication Critical patent/WO2005065672A1/fr
Priority to NO20063144A priority patent/NO20063144L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Definitions

  • the present invention relates to a composition capable of inhibiting or retarding aging.
  • the antiaging effect has so far been considered from two aspects.
  • One is the effect on apparent aging, namely skin aging and, specifically, this includes an improvement of wrinkles and freckles. This effect may include retention of skin elasticity and moisture, and the like effects.
  • preparations for external use such as cosmetics have claimed such effects, and some products have actually proved to be effective in humans.
  • the other is the effect on bodily aging except for skin aging.
  • antioxidant activity-based supplements may be mentioned.
  • the antiaging effects claimed by these supplements are just analogized from the effects obtained in vi tro; and not demonstrated from the effects obtained in vivo .
  • Oxidized coenzyme Qio is on sale as an antiaging supplement. In fact, however, its efficacy has not been demonstrated but is merely an analogy from the antioxidant activity of coenzyme Qio- Further, reduced coenzyme Qio has not yet been commercialized because of its ready oxidizability; there is no knowledge in the art about its actual antiaging effect, like oxidized coenzyme Qio.
  • the present invention relates to an antiaging composition which comprises, as an active ingredient, a reduced coenzyme Q represented by the following formula (1) :
  • n represents an integer of 1 to 12.
  • Coenzyme Q is an essential component widely distributed in living organisms, from bacteria to mammals, and is known to occur as a component of the electron transport system of mitochondria within the cells of living bodies. Coenzyme Q functions as an electron carrier in the electron transport system through repeating the cycle of oxidation-reduction in mitochondria. In addition, it is known that reduced coenzyme Q shows antioxidant activity. In humans, coenzyme Qio in which the side chain of coenzyme Q has 10 repeating units is the main component. As mentioned above, reduced coenzyme Q ⁇ 0 shows antioxidant activity in vi tro but oxidized coenzyme Q i0 does not show antioxidant activity.
  • Coenzyme Q comprises a reduced coenzyme Q represented by the following formula (1) : OH
  • n an integer of 1 to 12
  • an oxidized coenzyme Q represented by the following formula (2):
  • n an integer of 1 to 12.
  • the method of obtaining oxidized coenzyme Q and reduced coenzyme Q is not particularly restricted.
  • Employable are, for example, the method comprising obtaining coenzyme Q in the conventional manner such as synthesis, fermentation or extraction from a natural source, and then concentrating oxidized coenzyme Q fraction or reduced coenzyme Q fraction in the effluent by chromatography.
  • oxidized coenzyme Q is desired, methods known in the art can be used.
  • the antiaging composition of the invention is a composition comprising reduced coenzyme Q as an active ingredient.
  • coenzyme Q is not particularly restricted but may consist of a reduced form alone or may be a mixture with a oxidized form.
  • Coenzyme Q that can be used in the practice of the invention may be any of those having the repeating units in the side chain (n in the formulas) of 1 to 12, as illustrated by the above formulas (1) and (2) . Among them, however, one having the repeating units in the side chain of 10 (n in the above formulas (1) and (2) being 10), namely coenzyme Qio, is particularly preferably used.
  • the content of reduced coenzyme Q is preferably not lower than 20% by weight, more preferably not lower than 40% by weight, still more preferably not lower than 50% by weight, relative to the total amount of coenzyme Q.
  • the upper limit is preferably not higher than 99.5% by weight, but may be not higher than 95% by weight.
  • the content of reduced coenzyme Q is preferably 0.001 to 99% by weight, more preferably 0.01 to 99% by weight, still more preferably 0.1 to 50% by weight, relative to the whole composition.
  • the antiaging composition of the invention may contain, in addition to coenzyme Q, various additives acceptable from the medical or food hygiene law or the like viewpoint.
  • medicaments for the disease (s) concerned can be used in combination.
  • the above-mentioned additives are not particularly restricted but include, for example, excipients/diluents, disintegrants, lubricants, binders, coating agents, colorants, coagulation inhibitors, absorption promoters, solubilizing agents, stabilizers, health food materials, nutritional supplement materials (supplement materials) , and the like.
  • excipients/diluents are not particularly restricted but include, for example, white sugar, lactose, glucose, corn starch, mannitol, crystalline cellulose, calcium phosphate, calcium sulf te, and the like.
  • the disintegrants are not particularly restricted but include, for example, starch, agar, calcium citrate, calcium carbonate, sodium hydrogen carbonate, dextrin, crystalline cellulose, carboxymethylcellulose, tragacanth, and the like.
  • the lubricants are not particularly restricted but include, for example, talc, magnesium stearate, polyethylene glycol, silica, hydrogenated vegetable oils, and the like.
  • the binders are not particularly restricted but include, for example, ethylcellulose, methylcellulose, hydroxypropymethyllcellulose, tragacanth, shellac, gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, sorbitol, and the like.
  • the coating agents are not particularly restricted but include, for example, gum arabic, Opadry, prunella spike, castor wax, carboxyvinyl polymers, carmellose, hydrous silicon dioxide, magnesium silicate, vinyl acetate resins, stearic acid, cetanol, hydroxypropylmethylcellulose, and the like.
  • the colorants are not particularly restricted but those authorized to be added to drugs and/or foods, and the like can be used, for example.
  • the coagulation inhibitors are not particularly restricted but include, for example, stearic acid, talc, light silicic anhydride, hydrous silicon dioxide, and the like.
  • the absorption promoters are not particularly restricted but include, for example, higher alcohols, higher fatty acids, surfactants such as glycerol fatty acid esters, and the like.
  • the solubilizing agents are not particularly restricted but include, for example, organic acids such as fumaric acid, succinic acid, malic acid, and the like.
  • the stabilizers are not particularly restricted but include, for example, benzoic acid, sodium benzoate, ethyl parahydroxybenoate, and the like.
  • the health food materials are not particularly restricted but include, for example, Ka po (Chinese) medicines (e.g.
  • Irei-to (crude drug extract for treating stomach disorder, etc.), Unkei-to (crude drug extract for warming body, etc.), Unsei-in (crude drug extract for promoting blood circulation, etc.), Ogi-kenchu-to (extract of Astragalus membranaceus, etc.), Oren-gedoku-to (crude drug extract for reducing fever, inflammation, etc.), Oren- to (extract of Coptis chinensis, etc.), Kakkon-to (extract of Puerariae radix, etc.), Kami-kihi-to (crude drug extract for treating anemia, insomnia, neurosis, etc.), Kami-shoyo- san (crude drug extract for treating menstrual and climacteric disorder, etc.), Kam-baku-taiso-to (crude drug extract for treating night cry, convulsion, etc.), Kikyo-to (extract of Platycodon grandiflorum, etc.),
  • Livistona chinesis var. subglobosa Keigai-rengyo-to (crude drug extract for treating chronic paranasal sinusitis, acne, etc.), Keishi-ka-shakuyaku-daio-to (crude drug extract for treating stomach disorder, etc.), Keishi- ka-shakuyaku-to (extract of Cinnamomi cortex, Chinese peony, etc.), Keishi-ka-ryukotsu-borei-to (extract of Cinnamomi cortex, Ostrea gigas, etc.), Keishi-to (extract of
  • Cinnamomi cortex, etc. Keishi-ninjin-to (extract of Cinnamomi cortex, gensing, etc.), Keishi-bukuryo-gan (extract of Cinnamomi cortex, Poria cocos, etc.), Keihi-to (crude drug extract for treating digestive trouble, diarrhea, etc.), Koso-san (extract of Cyperus rotundus, etc.), Goko-to (crude drug extract for treating cough, asthma, etc.), Goshaku-san (crude drug extract for treating blood and water circulation, etc.), Gosha-jinki-gan (crude drug extract for improving body function, etc.), Gorin-san (crude drug extract for treating frequent urination, miction pain, etc.), Saikan-to (extract of Bupleurum chinense, etc.), Saiko-ka-ryukotsu-borei-to (extract of Bupleurum chinense, Ostrea gigas,
  • Bupleurum chinense, Cinnamomi cortex, etc. Saiko-seikan- to (extract of Bupleurum chinense, Scutellaria baicalensis Georgi, etc.), Saiboku-to (extract of Bupleurum chinense, Scutellaria baicalensis Georgi, Pinellia ternate, etc.), Sairei-to (crude drug extract for reducing inflammation, improving water circulation, etc.), Sansonin-to (extract of Zizyphus jujuba, etc.), Jiin-koka-to (crude drug extract for tempering cough) , Shigyaku-san (extract of Bupleurum chinense, etc.), Shikunshi-to (crude drug extract for improving stomach function, etc.), Shimotsu-to (extract of four crude drug species e.g.
  • Daio-kanzo-to extract of Rheum tanguticum and Glycyrrhiza uralensis
  • Daio-botampi-to extract of Rheum tanguticum, Paeonia suffruticosa, etc.
  • Dai-kenchu-to crude drug extract for reducing stomachache, etc.
  • Dai-saiko-to extract of Bupleurum chinense, Scutellaria baicalensis
  • green tea Japanese tea mixed with roasted rice, powdered green tea, green tea of middle grade, toasted tea, roasted tea, jasmine tea, oolong tea, tea, black tea, flower tea, blue tea, white tea, etc.
  • herbs e.g. Italian parsley, elecampane, olive, oregano, cardoon, chamomile, curry plant, catnip, caraway, Christmas rose, crimson clover, cornflower, common mallow, salad burnet, santolina, cinnamon, jasmine, stevia, sage, linden (lime), scented geranium, St.
  • herbs e.g. Italian parsley, elecampane, olive, oregano, cardoon, chamomile, curry plant, catnip, caraway, Christmas rose, crimson clover, cornflower, common mallow, salad burnet, santolina, cinnamon, jasmine, stevia, sage, linden (lime),
  • the nutritional supplement materials are not particularly restricted but include, for example, amino acids, metal ions, proteins, saccharides, fatty acids, yeast extracts, vegetable extracts, fish meat extracts, fruits, fruit extracts, and the like.
  • the antiaging composition of the invention may contain another antioxidant and the like.
  • the antioxidant includes, but is not limited to, for example, citric acid, citric acid derivatives, vitamin C, vitamin C derivatives, lycopene, vitamin A, carotenoids, vitamin B, vitamin B derivatives, flavonoids, polyphenols, glutathione, selenium, sodium thiosulfate, vitamin E, vitamin E derivatives, pyrroloquinoline quinone, pyrroloquinoline quinone derivatives, superoxide dismutase (SOD) , glutathione peroxidase, glutathione-S-transferase, glutathione reductase, catalase, ascorbic acid peroxidase, mixtures of these, and the like.
  • SOD superoxide dismutase
  • the method of producing the antiaging composition of the invention comprises mixing reduced coenzyme Q represented by the above formula (1) with acceptable additives .
  • the above-mentioned antiaging composition can be prepared, for example, by adding, mixing, spraying, including, conjugating, etc. the above-mentioned additives, antioxidants and the like, according to need, to/with reduced coenzyme Q obtained as mentioned above.
  • the composition can also be obtained by adding various additives, solvents, bases and the like, which are accepted as pharmaceutical and/or food additives, to reduced coenzyme Q and subjecting the resulting mixture to processing for preparing various adequate dosage forms, namely to granulation, coating, microencapsulation, inclusion, incorporation, emulsification, suspension, or the like.
  • the dosage form of the antiaging composition of the invention may be either liquid or solid.
  • various methods are employable such as oral administration, injection, nasal administration, administration in the form of an ophthalmic solution or suppositories, or eating of a coenzyme Q-containing foodstuff.
  • the composition of the invention can be administered by any other route than oral administration without any problem.
  • the recommendable method of administration includes, but is not limited to, administration in the form of suppositories, external preparations for dermal application, or the like.
  • the dose of the antiaging composition of the invention as expressed in terms of the amount of coenzyme Q is preferably 30 to 1,200 g, more preferably 50 to 800 mg, still more preferably 100 to 300 mg, per day per human.
  • the antiaging composition of the invention can prevent or retard the aging of humans and/or animals.
  • aging refers, for example, to blunting of behavior, for example decreased activity or decreased passivity, backbone bending, loss of hair, corneal clouding, inflammation periphery of the eye and/or ear, and the like.
  • the administration of the antiaging composition of the invention can delay the onset of, or ameliorate, these aging-associated symptoms.
  • aging-accelerated model mice can be used as an in vivo evaluation model. This mouse is a model mouse discovered and bred at Kyoto University, Japan, which develops the state of aging early and markedly. This mouse shows the state of aging quite similar to that of humans, and is a useful model animal for in vivo testing for antiaging effects .
  • the method of preventing aging in an animal according to the invention comprises administering the above ' antiaging composition to the target animal.
  • the animal includes mammals, fish, birds, reptiles, insects, and the like. Preferred as the animal are mammals, for example humans.
  • the term "administering" includes, within the meaning thereof, topical, enteral, e.g. oral or rectal, or parenteral administration. As for the route of administration, oral administration is preferred.
  • the reduced coenzyme Q-containing composition of the invention produces excellent effect on preventing or retarding aging.
  • Fig. 1 is a graph showing the increases in aging degree score in aging-accelerated model mice fed with reduced coenzyme Qio.
  • the ordinate denotes the aging degree score.
  • the significant difference testing was performed in the manner of Student's t test.
  • the mark * indicates that there is a significant difference relative to the control group at the degree of risk of 5%, and ** indicates that there is a significant difference relative to the control group at the degree of risk of 1%.
  • the abscissa denotes the age of mice in months. Fig.
  • FIG. 2 is a graph showing the increases in aging degree score in aging-accelerated model mice fed with oxidized coenzyme Qio-
  • the ordinate denotes the aging degree score.
  • the significant difference testing was performed in the manner of Student's t test.
  • the mark * indicates that there is a significant difference relative to the control group at the degree of risk of 5%.
  • the abscissa denotes the age of mice in months.
  • the slurry obtained was filtered under reduced pressure, the wet crystals were washed in sequence with cold ethanol, cold water and cold ethanol (the temperature of the cold solvents used being 2°C) , and the wet crystals were further dried under reduced pressure (20 to 40°C, 1 to 30 mmHg) to give 97 g of reduced coenzyme Qio (containing about 1% of oxidized coenzyme Q i0 ) as white dry crystals. All the operations other than drying under reduced pressure were carried out in a nitrogen atmosphere.
  • This heptane phase was subjected to solvent substitution under reduced pressure for preparing a 7% (w/w) ethanol solution of reduced coenzyme Qio at 50°C (the solution containing 100 g of reduced coenzyme Q i0 ) .
  • 50 g of water was added to this ethanol solution, and the mixture was cooled to 2°C at a cooling rate of 10°C/hour while stirring to precipitate crystals. All the operations were carried out in a nitrogen atmosphere.
  • the slurry thus obtained was filtered under reduced pressure, and the wet crystals were washed in sequence with cold ethanol, cold water and cold ethanol (the temperature of the cold solvents used for washing being 2°C) .
  • the wet crystals were further dried under reduced pressure (20 to 40°C, 1 to 30 mmHg) to give 97 g of reduced coenzyme Q i0 (containing about 1% of oxidized coenzyme Qio) as white dry crystals.
  • Example 1 Aging preventing (retarding) effect in aging- accelerated model mice
  • SAMP1 3-week-old females
  • a feed CE-2, product of CLEA Japan, Inc.
  • reduced coenzyme Qio containing about 1% of oxidized coenzyme Q 10
  • the dose of reduced coenzyme Qio as estimated from the feed consumption and animal weight corresponded to about 150 to 250 mg/kg/day.
  • a control group was given the feed alone (CE-2, product of CLEA Japan, Inc. ) .
  • the aging-accelerated model mice used were model mice discovered and bred at Kyoto University which develop the state of aging early and markedly. These mice show the state of aging quite similar to that of humans, and are useful model animals for in vivo testing for antiaging effects.
  • the aging degree scoring system employed was the scoring system established by the Council for SAM Research.
  • Example 1 The test of Example 1 was performed in the same manner except that oxidized coenzyme Qio was used in lieu of reduced coenzyme Qio.
  • the dose of oxidized coenzyme Qio as estimated from the feed consumption and animal body weight corresponded to about 150 to 250 mg/kg/day, and it was nearly the same as the dose of reduced coenzyme Q ⁇ 0 .
  • the results are shown in Fig. 2.
  • the increases in aging degree score were suppressed to a certain extent but the aging preventing effect thereof was weak as compared .with that of reduced coenzyme Qio.
  • Preparation Example 2 Capsules Using the materials specified below, a powder preparation was prepared in the same manner as in Preparation Example 1. This powder was filled into gelatin capsules in the conventional manner. The filled capsules were sealed and packed in a nitrogen atmosphere and stored in a refrigerator. Reduced coenzyme Qio 19.8 parts by weight Oxidized coenzyme Qio 0.2 parts by weight Microcrystalline cellulose 40 parts by weight Corn starch 20 parts by weight Lactose 65 parts by weight Magnesium stearate 3 parts by weight Polyvinylpyrrolidone 2 parts by weight
  • Oxidized coenzyme Qio 0.2 parts by weight Corn starch 25 parts by weight Lactose 15 parts by weight Carboxymethylcellulose calcium 10 parts by weight Microcrystalline cellulose 40 parts by weight Polyvinylpyrrolidone 5 parts by weight Magnesium stearate 3 parts by weight Talc 10 parts by weight
  • the reduced coenzyme Q-containing composition of the invention produces excellent effect on preventing or retarding aging.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une composition pouvant efficacement retarder ou prévenir le développement d'une baisse d'énergie, d'un changement de l'apparence etc. chez les êtres humains et les animaux en raison du vieillissement, laquelle composition est sans danger, même lorsqu'elle est prise sur une longue durée. Cette invention concerne une composition antivieillissement qui comprend une coenzyme Q réduite comme ingrédient actif. Le fait de nourrir des souris qui développent les symptômes du vieillissement précoce (souris modèles du vieillissement accéléré) avec des aliments contenant la coenzyme Q10 réduite pendant une durée prolongée permet d'empêcher et de retarder le processus de vieillissement. En outre, les souris modèles du vieillissement accéléré nourries avec la coenzyme Q10 réduite pendant une durée prolongée ne présentent aucun symptôme toxique. Il s'avère donc que la composition antivieillissement de cette invention comprenant une composition contenant cette substance peut être transformée en une composition antivieillissement sans danger pouvant être prise pendant une durée prolongée.
PCT/JP2005/000430 2004-01-08 2005-01-07 Composition antivieillissement WO2005065672A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005204044A AU2005204044B2 (en) 2004-01-08 2005-01-07 Antiaging composition
JP2006520582A JP2007517761A (ja) 2004-01-08 2005-01-07 抗老化用組成物
CA002550186A CA2550186A1 (fr) 2004-01-08 2005-01-07 Composition antivieillissement
EP05703669A EP1701716A1 (fr) 2004-01-08 2005-01-07 Composition antivieillissement
NO20063144A NO20063144L (no) 2004-01-08 2006-07-06 Anti-aldringspreparater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004002863 2004-01-08
JP2004-002863 2004-01-08

Publications (1)

Publication Number Publication Date
WO2005065672A1 true WO2005065672A1 (fr) 2005-07-21

Family

ID=34747062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/000430 WO2005065672A1 (fr) 2004-01-08 2005-01-07 Composition antivieillissement

Country Status (10)

Country Link
EP (1) EP1701716A1 (fr)
JP (1) JP2007517761A (fr)
KR (1) KR20060134057A (fr)
CN (1) CN1909895A (fr)
AU (1) AU2005204044B2 (fr)
CA (1) CA2550186A1 (fr)
NO (1) NO20063144L (fr)
RU (1) RU2006128735A (fr)
TW (1) TW200526193A (fr)
WO (1) WO2005065672A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034852A1 (fr) 2005-09-22 2007-03-29 Kaneka Corporation Composition destinée à prolonger la vie et procédé destiné à prolonger la vie
WO2013066623A1 (fr) * 2011-11-03 2013-05-10 Vaskin, Llc Application anti-vieillissement et méthode de traitement du vieillissement
US8962684B2 (en) 2009-09-29 2015-02-24 Shiseido Company, Ltd. Antioxidant composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007028997A (ja) * 2005-07-27 2007-02-08 Kanebo Seiyaku Kk 生薬エキス配合流動食及びその使用
WO2015163443A1 (fr) * 2014-04-25 2015-10-29 ヤクルトヘルスフーズ株式会社 Agent permettant de retarder l'apparition de symptômes physiques associés au vieillissement
CN104474527B (zh) * 2014-11-24 2015-10-07 南京泛成生物化工有限公司 一种含富硒酵母的组合物及其应用
CN111603552A (zh) * 2020-07-02 2020-09-01 中健智诊(重庆)生物研究院 一种抗衰老组合物及其应用
CN111973477A (zh) * 2020-09-04 2020-11-24 湖南御家化妆品制造有限公司 一种艾地苯醌、微晶纤维素复合载体的制备方法及化妆品

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4156718A (en) * 1976-11-19 1979-05-29 The New England Institute, Inc. Control and reversal of the immunological senescence
WO1998043617A2 (fr) * 1997-03-27 1998-10-08 Sole Michael J Composition nutritionnelle servant a ameliorer la capacite energetique cellulaire
WO2000023069A1 (fr) * 1998-10-21 2000-04-27 Sigma-Tau Healthscience S.P.A. Composition renfermant de l'ubiquinone destinee a favoriser le transport intramitochondrial des ubiquinones, et procede d'utilisation de cette composition
WO2001052822A1 (fr) * 2000-01-20 2001-07-26 Chopra Raj K Forme reduite de coenzyme q dans des formes posologiques stables a haute biodisponibilite et applications correspondantes
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US20030028054A1 (en) * 2001-06-14 2003-02-06 West Daniel David Synthesis of coenzyme q10 ubiquinone
JP2003135022A (ja) * 2001-10-31 2003-05-13 Crescendo Corporation コエンザイムｑ１０
GB2402334A (en) * 2003-06-06 2004-12-08 Nbty Inc Coenzyme-Q10 containing pharmaceutical composition with improved bioavailability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329513B (en) * 2001-10-12 2010-09-01 Kaneka Corp Use of reduced coenzyme q for lessening oxidative stress
TWI322008B (en) * 2003-01-31 2010-03-21 Kaneka Corp Fatigue improving agent including reduced coenzyme q10

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4156718A (en) * 1976-11-19 1979-05-29 The New England Institute, Inc. Control and reversal of the immunological senescence
WO1998043617A2 (fr) * 1997-03-27 1998-10-08 Sole Michael J Composition nutritionnelle servant a ameliorer la capacite energetique cellulaire
WO2000023069A1 (fr) * 1998-10-21 2000-04-27 Sigma-Tau Healthscience S.P.A. Composition renfermant de l'ubiquinone destinee a favoriser le transport intramitochondrial des ubiquinones, et procede d'utilisation de cette composition
WO2001052822A1 (fr) * 2000-01-20 2001-07-26 Chopra Raj K Forme reduite de coenzyme q dans des formes posologiques stables a haute biodisponibilite et applications correspondantes
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US20030028054A1 (en) * 2001-06-14 2003-02-06 West Daniel David Synthesis of coenzyme q10 ubiquinone
JP2003135022A (ja) * 2001-10-31 2003-05-13 Crescendo Corporation コエンザイムｑ１０
GB2402334A (en) * 2003-06-06 2004-12-08 Nbty Inc Coenzyme-Q10 containing pharmaceutical composition with improved bioavailability

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1993, ERNSTER L ET AL: "Ubiquinol: an endogenous antioxidant in aerobic organisms.", XP002331509, Database accession no. NLM8241707 *
DATABASE WPI Section Ch Week 200367, Derwent World Patents Index; Class B05, AN 2003-700882, XP002331510 *
NOHL H ET AL: "Antioxidant-derived prooxidant formation from ubiquinol.", FREE RADICAL BIOLOGY & MEDICINE. OCT 1998, vol. 25, no. 6, October 1998 (1998-10-01), pages 666 - 675, XP002331508, ISSN: 0891-5849 *
See also references of EP1701716A1 *
SINATRA DREW S ET AL: "The effects of Coenzyme Q10 on locomotor and behavioral activity in young and aged C57BL/6 mice.", BIOFACTORS (OXFORD, ENGLAND) 2003, vol. 18, no. 1-4, 2003, pages 283 - 287, XP008048329, ISSN: 0951-6433 *
THE CLINICAL INVESTIGATOR. 1993, vol. 71, no. 8 Suppl, 1993, pages S60 - S65, ISSN: 0941-0198 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034852A1 (fr) 2005-09-22 2007-03-29 Kaneka Corporation Composition destinée à prolonger la vie et procédé destiné à prolonger la vie
US8962684B2 (en) 2009-09-29 2015-02-24 Shiseido Company, Ltd. Antioxidant composition
WO2013066623A1 (fr) * 2011-11-03 2013-05-10 Vaskin, Llc Application anti-vieillissement et méthode de traitement du vieillissement

Also Published As

Publication number Publication date
RU2006128735A (ru) 2008-02-20
EP1701716A1 (fr) 2006-09-20
JP2007517761A (ja) 2007-07-05
AU2005204044B2 (en) 2010-07-22
AU2005204044A1 (en) 2005-07-21
NO20063144L (no) 2006-10-09
TW200526193A (en) 2005-08-16
CA2550186A1 (fr) 2005-07-21
KR20060134057A (ko) 2006-12-27
CN1909895A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
AU2005204044B2 (en) Antiaging composition
JP5352235B2 (ja) 酸化型補酵素ｑ１０含有高吸収性経口用組成物
US20050154066A1 (en) Antiaging composition
EP1938810B1 (fr) Agent d'amelioration pour le syndrome metabolique
JP2005510509A (ja) 放射線障害の予防、軽減、及び治療用の栄養性サプリメント及びその方法
EP2005951A9 (fr) Agent pour améliorer des fonctions cellulaires du système nerveux
JP2008537678A (ja) リグナン含有組成物
TW200843726A (en) Agent for relief or prevention of xerostomia
US20100150894A1 (en) Composition for prevention of cancer
CA2907886A1 (fr) Effet neuroprotecteur des carotenoides dans le cerveau
WO2008034316A1 (fr) Préparation de composés capable de reduction rapide de stress oxidatif et son procédé de préparation
EP2836210A2 (fr) Agent permettant d'induire la synthèse de protéines de choc thermique dans des cellules humaines et animales; préparation cosmétique permettant d'améliorer les processus de réparation; préparation cosmétique permettant de réduire les effets secondaires d'interventions de chirurgie esthétique agressives; complément alimentai
US20100234385A1 (en) Compsition Containing Biopterin and Method for Using The Same
JP2009007346A (ja) 糖尿病併発疾病予防剤
KR20160035641A (ko) 플로레틴 술폰산염 및 이를 포함하는 피부 상태 개선용 조성물
KR20060107825A (ko) 간 기능 보호 작용 조성물
WO2020077915A1 (fr) Nouvelle utilisation d'hydroxytyrosol et d'un dérivé de celui-ci dans la préparation d'un produit antidépresseur
KR20200063772A (ko) 진세노사이드 Re를 포함하는 거저리 유충 추출물을 유효성분으로 포함하는 항염증용 조성물
JPH07330593A (ja) 疲労改善剤
WO2013125135A1 (fr) Composition favorisant l'absorption d'anthocyane
US20090246185A1 (en) Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent
JP2009126814A (ja) 高尿酸血症の予防または改善剤
WO2007034852A1 (fr) Composition destinée à prolonger la vie et procédé destiné à prolonger la vie
ES2900604T3 (es) Composición que comprende coenzima Q10 y piperina
CN116832046A (zh) 一种基于维生素k2提高老年人生命质量的药物组合物及其制备方法与应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2550186

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006520582

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005204044

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1874/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580002082.2

Country of ref document: CN

Ref document number: 2005703669

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005204044

Country of ref document: AU

Date of ref document: 20050107

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005204044

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067015919

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006128735

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005703669

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067015919

Country of ref document: KR